Annexon, a biotechnology company focused on developing therapies for autoimmune and neurodegenerative diseases, recently announced promising topline results from a real-world evidence study comparing its innovative treatment, ANX005, to conventional therapies, specifically intravenous immunoglobulin (IVIg) and plasma exchange (PE), in a matched cohort of Guillain-Barré syndrome (GBS) patients. Guillain-Barré syndrome is a rare neurological disorder characterized by rapid-onset muscle weakness and, in severe cases, paralysis. Traditional treatment options include IVIg and PE, both of which aim to alleviate symptoms and improve recovery rates. However, some patients may experience suboptimal outcomes, sparki...
In recent developments within the field of ophthalmology, Annexon has made significant strides in the treatment of geographic atrophy (GA) associated with age-related macular degeneration (AMD). The company has officially initiated patient dosing in the Phase 3 ARCHER II clinical trial for its investigational C1q inhibitor, ANX007. This groundbreaking study is anticipated to provide topline data in the second half of 2026, potentially paving the way for a new therapeutic approach to a condition that currently lacks effective treatment options. Understanding Geographic Atrophy and Its ImpactGeographic atrophy is characterized by the progressive degeneration of retinal pigment epithelial cells, leading to the ...
Annexon s C1q Blocking Antibody ANX005 Demonstrates Significant Efficacy in Pivotal Phase 3 TrialIn a landmark achievement that could revolutionize the treatment landscape for Guillain-Barré Syndrome (GBS), Annexon Biosciences has announced the positive topline results of its pivotal Phase 3 trial for their first-in-class C1q blocking antibody, ANX005. The trial results not only met the primary endpoint but delivered a highly statistically significant and clinically meaningful improvement in patients, heralding a new era in the management of this debilitating neurological disorder. Trailblazing Results and Statistical SignificanceThe Phase 3 trial for ANX005 exhibited a 2.4-fold improvement in the Guillain...
Experimental drug discovery and development is a rigorous, scientific process, often involving years of intensive research, testing, and hefty investment. Annexon Inc., a clinical-stage biopharmaceutical company, is no stranger to this process and recently completed phase I trials for ANX1502, an orally administered small molecule inhibitor, designed to interfere with the classical complement pathway. Annexon s preliminary findings revealed that the drug had met target levels of activity, with daily dosing showing a supportive impact on pharmacodynamic biomarker of complement activity. The classical complement pathway fundamentally plays an essential role in our immune system s operation. It helps recognize ...
Sources:
Annexon Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Annexon Inc’s corporate clients.
For your research, we’ve provided 9 tables on Annexon Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
